Immediate Contraception Ups Continuance Rates

BY DIANA MAHONEY
New England Bureau

BOSTON — The immediate initiation of depot medroxyprogesterone acetate to adolescent and young adult women seeking the contraceptive injection resulted in higher continuation rates and substantially diminished unintended pregnancy rates at 6 months, compared with the use of alternative, short-term hormonal methods meant to bridge the period between initial request and injection at a later date, Vaughn I. Rickert, Psy.D., said at the annual meeting of the Society for Adolescent Medicine.

In a study of 334 young women ages 14-26 years who asked for depot medroxyprogesterone (DMPA) during a reproductive health visit at an urban family planning clinic, 101 women were randomized to receive their first DMPA (Depo Provera) injection at the conclusion of the visit, and 233 were randomized to an alternative “quick start” bridge condition whereby they were offered their choice of either oral contraceptive pills, the transdermal patch, or the vaginal ring, said Dr. Rickert of the Mailman School of Public Health at Columbia University in New York.

In a previous study, the Columbia investigators determined that patients who immediately initiated oral contraception at the time of their clinic visit (after a negative urine pregnancy test) were significantly more likely to continue taking the oral contraceptive than were a control group of women who were provided with conventional instructions to wait until their menses began before starting oral contraception (Contraception 2002;66: 141-5).

Historically, the rationale for waiting to initiate hormonal contraception “was to be sure the patient was not pregnant and to keep from altering the bleeding pattern,” according to Dr. Rickert. “Unfortunately, with the delayed initiation, many women don’t take their first pill, and their motivation wanes.” Similarly, asking women to return to the clinic at a later date for a DMPA injection means that some won’t come back for it, thus increasing the likelihood for unintended pregnancies.

The immediate contraception protocol was designed to avoid this outcome, according to Dr. Rickert. While the earlier study looked specifically at the efficacy of the approach with respect to oral contraceptives, the current study sought to determine whether immediate access to DMPA would lead to greater method continuation—and thus pregnancy prevention—over a 6-month period, compared with delaying the injection and providing alternative contraceptive options for the interim period.

All the women enrolled in the study had a negative urine pregnancy test at the time of their initial clinic visit, and none were breast-feeding or currently using other forms of hormonal contraception. In addition, none of the women had received a DMPA injection within the previous 14 weeks nor had any medical contraindications to hormonal contraception, said Dr. Rickert.

All the subjects in both conditions underwent a history, physical, pregnancy test, and structured interview at the initial visit. All were instructed to return to the clinic in 21 days for a repeat urine pregnancy test and, for those assigned to the alternative condition, to receive their first DMPA injection, said Dr. Rickert. In addition, the women were followed through two subsequent appointments for DMPA injections and structured interviews.

The DMPA injections were discontinued in women in whom pregnancy was
detected at any visit, in those who refused injection at any visit, or in those for whom more than 98 days had passed since their previous injection, said Dr. Rickert.

Of the 233 women randomized to the quick start bridge condition, 95 chose oral contraceptive pills, 100 chose the transdermal patch, and 38 chose the vaginal ring. Emergency contraception was provided to 41% of the entire cohort—31 patients in the Depo group and 83 in the bridge group—at the initial visit. Of women who received immediate injection of DMPPA, 7 never returned for a follow-up visit, compared with 11 in the bridge group who never returned for a follow-up visit.

As of February 2006, 278 of the women had completed the study. Of this population, 54 were between the ages of 14 and 17 years, 118 were between the ages of 18 and 21, and 106 were between 22 and 26. The sample was more than 90% Latino and approximately 7% African American. “No significant differences were found in baseline demographic or reproductive characteristics,” Dr. Rickert reported.

Bivariate analysis showed no statistically significant difference in the 21-day return rates among those who began DMPPA immediately and those who were randomized to use a bridge method prior to the first injection. In addition, “rates of patient satisfaction [with the respective contraceptive protocols] between the two groups were not different at the second and third injections,” said Dr. Rickert.

However, “continuation rates were statistically higher at 6 months in the Depo group compared to the bridge group, meaning that more women in the Depo group received their third injection,” he said. Also, the Depo group had significantly fewer pregnancies (2, compared with 23 in the bridge group) across the study period.”

Other factors independently associated with 6-month DMPPA continuation rates included partners’ awareness of DMPPA use, returning for the pregnancy test visit, and history of emergency contraceptive pill use, “suggesting continuation is also affected by behaviors consistent with intentions not to become pregnant,” said Dr. Rickert.

These findings support the idea that immediate administration of DMPPA with little adverse effect might have a significant impact on contraceptive continuation as well as on the prevention of unintended pregnancies, Dr. Rickert concluded.

**DETROL LA is the #1 prescribed brand for OAB**

DETROL LA is the #1 prescribed brand for OAB—

with **BIG REDUCTIONS** in OAB symptoms\(^1\)\(^2\)

**Total patient population**

<table>
<thead>
<tr>
<th>Placebo</th>
<th>DETROL LA 4 mg qd</th>
</tr>
</thead>
<tbody>
<tr>
<td>33% (n=607)</td>
<td>71% (n=507)</td>
</tr>
</tbody>
</table>

**Severe urgency/incontinence population**

<table>
<thead>
<tr>
<th>Placebo</th>
<th>DETROL LA 4 mg qd</th>
</tr>
</thead>
<tbody>
<tr>
<td>30% (n=210)</td>
<td>68% (n=171)</td>
</tr>
</tbody>
</table>

Van Kerrebrouck et al. *Urology*. 2001;57:414–421.\(^1\) A 12-week, placebo-controlled Registration Study. (See full study description on next page.)

Landis et al. *J Urol*. 2004;171:752–756.\(^2\) A post hoc analysis of the Registration Study. (See full study description on next page.)

**DETROL LA** is indicated for the treatment of overactive bladder with symptoms of urge incontinence, urgency, and frequency. DETROL LA is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma and in patients who have demonstrated hypersensitivity to the drug or its ingredients. Patients with the following conditions should be treated with caution: renal impairment, bladder outflow obstruction, gastrointestinal obstructive disorders, controlled narrow-angle glaucoma, and significantly reduced hepatic function. Dry mouth was the most frequently reported adverse event (DETROL LA 23% vs placebo 8%); others (≥4%) included headache (DETROL LA 6% vs placebo 4%), constipation (DETROL LA 6% vs placebo 4%), and abdominal pain (DETROL LA 4% vs placebo 2%).

\(^1\) Source: IMS Midas Global Sales Audit, Verispan longitudinal data, based on total prescriptions of DETROL and DETROL LA for OAB from April 1998 to August 2005.


Please see important product information on next page.